Executive Summary
Decentralized clinical trials are changing how pharmaceutical companies think about the economics of clinical research.
Traditional trials often require patients to travel to clinical sites for assessments, investigators to manage extensive onsite activities, and sponsors to coordinate complex networks of physical locations. Decentralized approaches use technologies such as telemedicine, remote monitoring, wearable devices, electronic consent, home health services, and direct-to-patient logistics to move selected trial activities closer to participants.
The economic opportunity is significant, but it is more nuanced than simply reducing the number of site visits.
Decentralized trials can potentially improve patient recruitment and retention, expand geographic access, reduce travel-related burdens, and make some trial activities more efficient. At the same time, technology platforms, home services, logistics, training, data integration, and cybersecurity can introduce new costs.
The economic value therefore depends on how decentralized models are designed and which trial activities are moved away from traditional sites.
For pharmaceutical companies, the central question is becoming less about whether decentralized trials are cheaper and more about where decentralization can improve the overall economics of clinical development.
Why Do Clinical Trials Need a Different Economic Model?
Clinical trials are among the most expensive components of drug development.
Sponsors must manage investigators, sites, patients, monitoring, data collection, laboratory testing, regulatory requirements, and operational logistics.
Patient recruitment and retention can also create significant costs. Delays in enrollment can extend development timelines, while high dropout rates can require additional recruitment and operational resources.
Decentralized approaches can address some of these pressures by making participation more convenient and expanding access beyond traditional clinical sites.
The economic benefit may therefore come from improving the entire development process rather than reducing one specific cost category.
Can Decentralized Trials Reduce Site Costs?
Site costs represent a significant component of clinical trial budgets.
Decentralized models can reduce the need for certain onsite activities by shifting selected assessments to patients’ homes or digital environments.
However, they do not necessarily eliminate clinical sites.
Many trials still require investigators, physical examinations, imaging, laboratory testing, or procedures that cannot be performed remotely.
The economic model is therefore increasingly moving toward hybrid trials, where conventional site-based activities are combined with remote services.
This allows sponsors to decentralize activities where doing so creates measurable value while retaining physical sites for procedures that require them.
How Can Recruitment Affect Trial Economics?
Recruitment delays can have substantial financial consequences.
A trial that struggles to find eligible participants may take longer to complete, delaying subsequent development milestones and potentially extending the period before a medicine reaches the market.
Decentralized approaches can expand the potential recruitment pool by reducing geographic barriers.
Patients who live far from specialized research centers may be able to participate through remote visits or local services.
This can be particularly relevant for diseases where eligible patients are geographically dispersed.
The economic value of broader recruitment can therefore extend beyond direct recruitment costs.
Can Decentralization Improve Patient Retention?
Patient dropout can affect both the cost and statistical efficiency of clinical trials.
Travel requirements, time away from work, transportation difficulties, and repeated site visits can make participation burdensome.
Remote visits, home nursing, digital communication, and remote data collection can reduce some of these barriers.
Better retention can help sponsors avoid the need to recruit replacement participants and can improve continuity of collected data.
The economic impact may therefore come from reducing trial disruption rather than simply reducing the cost of individual visits.
What New Costs Do Decentralized Trials Create?
Decentralization does not make clinical trials cost-free.
Sponsors may need to invest in:
- Digital trial platforms
- Wearable and connected devices
- Home healthcare services
- Direct-to-patient logistics
- Telemedicine infrastructure
- Data integration
- Technical support
- Cybersecurity
Some of these costs are variable and depend on the number of participants and the complexity of the protocol.
Sponsors therefore need to compare the total cost of decentralized operations with the costs and potential delays associated with traditional trial models.
How Does Technology Affect the Economics?
Technology is central to decentralized trials.
Electronic consent, electronic patient-reported outcomes, telemedicine, remote monitoring, wearable sensors, and digital endpoints can reduce the need for some physical interactions.
However, each technology introduces implementation and management requirements.
Sponsors need to consider device distribution, participant training, technical support, data quality, system validation, and integration with existing clinical trial infrastructure.
The economic benefit depends on whether technology simplifies the overall trial rather than simply adding another layer of infrastructure.
Can Decentralized Trials Improve Data Collection?
Remote technologies can create opportunities to collect data more frequently and in participants’ normal environments.
Wearables, connected devices, and digital assessments can generate longitudinal information that may be difficult to capture through occasional site visits.
More continuous data can potentially provide greater visibility into patient experiences and treatment responses.
However, more data does not automatically mean better data.
Sponsors must ensure that digital measurements are scientifically meaningful, validated where required, and operationally reliable.
Poor-quality or incomplete digital data can create additional costs rather than savings.
What Role Does Protocol Design Play?
The economics of decentralization are closely connected to protocol complexity.
A highly complex protocol with frequent procedures, specialized imaging, and intensive onsite assessments may offer limited opportunities for decentralization.
A simpler protocol may allow more activities to be performed remotely.
Sponsors can therefore influence trial economics before the study begins.
Protocol design should consider which assessments are truly necessary, where they need to occur, and whether technology can reduce unnecessary participant and site burden.
This can create a more efficient operating model without compromising scientific rigor.
How Can Decentralized Trials Affect Trial Timelines?
Time is an important economic variable in drug development.
Delays can increase operational expenses and postpone important development decisions.
If decentralized approaches improve recruitment, reduce dropout, or simplify certain trial activities, they may help shorten overall timelines.
The value of this acceleration can potentially exceed the direct savings from individual trial activities.
For pharmaceutical companies, faster access to reliable clinical evidence can have strategic and financial importance, particularly in competitive therapeutic areas.
What Are the Biggest Economic Challenges?
The economics of decentralized clinical trials remain highly dependent on study design and execution.
Common challenges include technology integration, fragmented vendors, patient support requirements, regulatory differences across markets, data quality, and the cost of maintaining both remote and traditional infrastructure.
There is also a risk of over-decentralization.
Moving an activity away from a clinical site simply because technology allows it does not necessarily create value.
The objective should be to identify where decentralization improves the participant experience, operational efficiency, data quality, or development timeline.
How Should Sponsors Evaluate ROI?
Sponsors need broader metrics than simple cost-per-patient comparisons.
The economic assessment can include:
- Recruitment speed
- Patient retention
- Site productivity
- Trial duration
- Cost per enrolled patient
- Data completeness
- Protocol adherence
- Participant burden
- Operational scalability
These measures can provide a more complete picture of whether decentralization is producing value.
The most important question is whether the model improves the economics of the entire trial rather than optimizing one isolated activity.
What Will the Future Economics of DCTs Look Like?
The future is likely to involve increasingly flexible clinical trial models rather than a complete replacement of traditional sites.
Sponsors could determine which activities should occur at research centers, which can be performed remotely, and which can be supported through local healthcare providers.
AI may further improve this model by helping sponsors identify appropriate trial designs, predict recruitment challenges, optimize site networks, and monitor operational performance.
Over time, reusable digital infrastructure could also reduce the cost of implementing decentralized capabilities across multiple studies.
Conclusion
The economics of decentralized clinical trials extend beyond the question of whether remote trials cost less than traditional trials.
Their potential value comes from changing how clinical research is delivered.
By reducing participant burden, expanding recruitment opportunities, improving retention, enabling richer data collection, and potentially shortening trial timelines, decentralized approaches can create economic benefits across the development lifecycle.
However, technology, logistics, home services, data integration, and operational complexity can introduce significant costs.
The strongest economic model is therefore unlikely to be fully decentralized or entirely site-based.
It will be a flexible approach that places each trial activity where it can be performed most efficiently while preserving scientific quality and patient safety.
For pharmaceutical companies, the next phase of decentralized clinical trials will be less about adopting individual technologies and more about designing clinical development models that optimize cost, speed, data quality, and patient participation simultaneously.
What Are Decentralized Clinical Trials?
Decentralized Clinical Trials (DCTs) allow some or all trial-related activities to take place outside traditional research sites. Instead of requiring every participant to travel to a hospital or research center, Clinical Trials may use telehealth consultations, home nursing visits, local laboratories, electronic consent, and remote data collection.
The economic appeal of Clinical Trials using decentralized approaches comes from changing where and how research activities are delivered. However, decentralized models are not automatically cheaper. Their financial value depends on the study design, patient population, technology requirements, and operational complexity. The FDA recognizes that decentralized elements can improve convenience and participation while requiring appropriate oversight and patient protection.
The Future Economics of Decentralized Clinical Trials
The economics of decentralized Clinical Trials will increasingly depend on selecting the right combination of remote and in-person activities. Hybrid designs may offer a practical balance by keeping procedures that require specialist facilities at research sites while moving suitable follow-up visits and assessments closer to participants.
Sponsors should evaluate each study individually, using pilot programs and operational data to test assumptions before scaling a decentralized model. Technology should be selected according to the protocol and participants’ needs rather than adopted simply because it is available.
Ultimately, decentralized Clinical Trials can improve accessibility and operational efficiency, but financial success depends on careful design, reliable data collection, participant support, and effective oversight. Organizations that measure both direct costs and the broader impact on recruitment, retention, and timelines will be better positioned to determine where decentralization delivers genuine value.
Hidden Costs and Financial Challenges
Although decentralized Clinical Trials offer potential savings, they require careful financial planning. Sponsors may need to invest in digital platforms, cybersecurity, device distribution, participant training, remote clinical services, and additional vendor management.
Other challenges include:
-
Inconsistent internet access or limited digital literacy among participants.
-
Device failures, missing measurements, and inconsistent data collection.
-
Complex coordination among local healthcare providers and central research teams.
-
Additional shipping, storage, and handling requirements for investigational medicines.
-
Privacy, informed-consent, and patient-safety obligations.
-
The need for in-person assessments when remote procedures are unsuitable.
The FDA emphasizes that Clinical Trials with decentralized elements must maintain appropriate investigator oversight, safety monitoring, and data quality. Regulatory requirements do not disappear when research activities move outside conventional sites.
1. Potentially Lower Participant-Related Costs
Travel, accommodation, missed work, and caregiver time can make participation expensive for patients. Decentralized Clinical Trials may reduce some of these burdens by allowing suitable assessments to happen remotely or closer to home.
2. Improved Recruitment and Retention
Clinical Trials can struggle when participants live far from research centers or face mobility and scheduling barriers. Remote options may expand the pool of eligible participants and make it easier for them to remain in a study. Better retention can reduce the financial impact of participant replacement and missing data, although these benefits are not guaranteed.
3. More Efficient Trial Timelines
Delays can increase staffing, site-management, and administrative costs. If decentralized Clinical Trials accelerate recruitment or reduce missed visits, sponsors may be able to shorten certain stages of study execution. The financial impact depends on whether remote delivery actually removes a bottleneck in the trial.
4. Broader Geographic Reach
Decentralized Clinical Trials can help sponsors reach people who live far from major academic medical centers. This may be particularly valuable for rare diseases and conditions affecting patients with limited mobility. Broader access may also improve participant diversity when digital access and other practical barriers are addressed.
